Compare GSK plc (GSK) vs SS&C Technologies Holdings Inc. Common Stock (SSNC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs SS&C Technologies Holdings Inc. Common Stock — how do they compare? GSK plc trades at $48.45 (market cap $96.45B), while SS&C Technologies Holdings Inc. Common Stock trades at $82.08 (market cap $19.25B). The key difference: GSK plc is far larger — about 5× SS&C Technologies Holdings Inc. Common Stock's market cap, and GSK plc pays the higher dividend (3.79%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and SS&C Technologies Holdings Inc. Common Stock for 0 Days on average.
| GSK | SSNC | |
|---|---|---|
Market Cap | $96.45B | $19.25B |
Volume | 7,087,457 | 1,341,767 |
Sector | Health | Technology |
52-Week High | $61.18 | $89.62 |
52-Week Low | $43.24 | $62.05 |
Typical Hold Time | 93 Days | 0 Days |
Enterprise Value | $116.51B | $26.59B |
Dividend Yield | 3.79% | 1.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.27, down 1.39% today, with a bearish technical signal from moving averages. The company shows strong profitability with 72.73% gross margins and 14.52% net income margin, supported by three consecutive quarterly earnings beats. Recent developments include a $750M cancer therapy acquisition and strategic focus on oncology growth targeting £40B in sales. Cash flow trends show consistent operational strength with $7.7B from operations in 2025.
GSK presents a mixed outlook with strong fundamentals offset by technical weakness. The stock offers value with a 14.84 P/E ratio and dividend yield, but faces headwinds from HIV patent expirations and bearish technical indicators. Analyst consensus leans cautious with 55% hold ratings, suggesting patience may be warranted despite the company's solid operational performance.
SSNC trades at $81.52, up 0.65% on the day, with a neutral technical signal. The company has consistently beaten earnings estimates in recent quarters (Q4 2025, Q1 2026, Q2 2026) and shows solid fundamentals, including a 13.16% net income margin and 12.73% ROE. Recent news highlights new client wins and AI-driven product enhancements, reinforcing its market position.
The outlook is positive, supported by strong analyst consensus (70.83% Buy rating) and a $91.50 price target, implying ~12% upside. Key risks include execution of growth initiatives and competitive pressures in the financial technology sector. The stock presents a compelling opportunity for investors seeking a fundamentally sound company with recurring revenue streams.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About SS&C Technologies Holdings Inc. Common Stock
SS&C Technologies Holdings, Inc. provides software and outsourced services for financial services and healthcare organizations, covering fund accounting, portfolio management, trading support, and regulatory reporting, and operates as a hedge fund and private equity administrator and mutual fund transfer agent.
Read more on SSNC →
